ASCO/IDSA 成人肿瘤发热性中性粒细胞减少门诊管理指南更新
ASCO与IDSA召集更新专家组,系统综述相关研究并新增6项荟萃分析与6项原始研究,更新成人肿瘤发热性中性粒细胞减少的门诊管理推荐。指南强调依据临床标准或MASCC风险指数判断门诊候选患者,并继续推荐初始经验性抗菌治疗在分诊后1小时内给药、出院前监测至少4小时。
要点
- 用临床标准或MASCC风险指数判断发热性中性粒细胞减少患者能否门诊管理。
- 初始经验性抗菌治疗应在分诊后1小时内给药,出院前监测至少4小时。
- 门诊经验性治疗推荐口服氟喹诺酮联合阿莫西林/克拉维酸(青霉素过敏用克林霉素),除非此前已用氟喹诺酮预防。
核心结论
- 临床判断用于确定发热性中性粒细胞减少患者是否适合门诊管理,可依据临床标准或经验证的工具如MASCC风险指数。
- 初始经验性抗菌治疗应在分诊后1小时内给药,出院前监测至少4小时。
- 门诊经验性治疗推荐口服氟喹诺酮联合阿莫西林/克拉维酸(青霉素过敏者用克林霉素),除非发热前已用氟喹诺酮预防。
- 初始广谱抗生素治疗2至3天不退热者应重新评估并考虑住院治疗。
研究设计与样本
- ASCO与IDSA召集更新专家组,对相关研究进行系统综述,推荐基于专家组证据审查。
- 更新系统综述新增6项荟萃分析和6项原始研究。
主要发现
- 更新系统综述新增6项荟萃分析和6项原始研究。
- 指南继续认可既往版本共识推荐:初始经验性抗菌治疗在分诊后1小时内给药并监测至少4小时再出院。
- 初始广谱抗生素2至3天不退热者应重新评估并考虑住院治疗。
关键数值与推荐
- 门诊候选患者判断可使用临床标准或经验证工具如MASCC风险指数。
- 初始经验性抗菌治疗应在分诊后1小时内给药,出院前监测至少4小时。
- 门诊经验性方案为口服氟喹诺酮联合阿莫西林/克拉维酸(青霉素过敏用克林霉素),除非此前已用氟喹诺酮预防。
- 初始广谱抗生素2至3天不退热者应重新评估并考虑住院。
临床怎么用
- 门诊管理决策应结合临床判断、心理社会与后勤因素综合评估。
- 符合条件者按推荐方案口服经验性抗菌治疗,并确保分诊后1小时内给药、出院前监测至少4小时。
- 初始治疗2至3天不退热者及时重新评估并考虑收住院。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel. Results Six new or updated meta-analyses and six new primary studies were added to the updated systematic review. Recommendation Clinical judgment is recommended when determining which patients are candidates for outpatient management, using clinical criteria or a validated tool such as the Multinational Association of Support Care in Cancer risk index. In addition, psychosocial and logistic considerations are outlined within the guideline. The panel continued to endorse consensus recommendations from the previous version of this guideline that patients with febrile neutropenia receive initial doses of empirical antibacterial therapy within 1 hour of triage and be monitored for ≥ 4 hours before discharge. An oral fluoroquinolone plus amoxicillin/clavulanate (or clindamycin, if penicillin allergic) is recommended as empirical outpatient therapy, unless fluoroquinolone prophylaxis was used before fever developed. Patients who do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen should be re-evaluated and considered as candidates for inpatient treatment. Additional information is available at www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki .
引用
- Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29461916. doi:10.1200/JCO.2017.77.6211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。